Hatem Hamood

Medicine & Life Sciences

1. Cancer Survivors 100%
2. Breast Neoplasms 65%
3. Confidence Intervals 34%
4. acipimox 29%
5. Cohort Studies 28%
6. Embolic Protection Devices 27%
7. Myocardial Infarction 26%
8. Survivors 24%
9. Quality of Life 24%
10. Hormones 24%
11. Aromatase Inhibitors 22%
12. Chronic Pain 21%
13. Financial Management 21%
14. Acute Coronary Syndrome 20%
15. Odds Ratio 19%
16. Hypertriglyceridemia 19%
17. ST Elevation Myocardial Infarction 19%
18. Feasibility Studies 17%
19. Hyperlipidemias 17%
20. Therapeutics 16%
21. Israel 15%
22. Information Storage and Retrieval 15%
23. Osteoporosis 15%
24. Cardiovascular Diseases 14%
25. Risk Assessment 14%
26. Intensive Care Units 14%
27. Hospital Emergency Service 13%
28. Radiotherapy 13%
29. Delivery of Health Care 13%
30. Mortality 13%
31. Equipment and Supplies 12%
32. Technology 11%
33. Hydroxymethylglutaryl-CoA Reductase Inhibitors 10%
34. Proportional Hazards Models 8%
35. Tamoxifen 8%
36. Health 8%
37. Angiotensin Receptor Antagonists 8%
38. Saphenous Vein 7%
39. Angiotensin-Converting Enzyme Inhibitors 7%
40. Outpatients 7%
41. Aspirin 7%
42. Registries 7%
43. Niacin 7%
44. Arteries 5%
45. Incidence 5%
46. Medical Records 5%
47. Pain 5%
48. Life Style 5%
49. Neoplasms 5%
50. Medication Adherence 5%